From Commercialization to Global Leadership: Innogen (2591.HK) Unlocks the Strategic Value of Its Ultra-Long-Acting GLP-1 Receptor Agonist

The release of Innogen's inaugural annual report following its Hong Kong listing serves not merely as a financial disclosure, but as a strategic milestone—offering investors and stakeholders critical ...
Hosted on MSN

Guangzhou Innogen’s efsubaglutide alfa gains national reimbursement approval

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Reuters

China's Innogen expects to complete weight-loss drug trials next year

SHANGHAI, July 1 (Reuters) - Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next year, its CEO said on Tuesday, the latest ...
Hosted on MSN

Guangzhou Innogen Expands Treasury Management with New Structured Deposits

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Guangzhou Innogen Pharmaceutical Group Co ...
Bloomberg L.P.

Innogen Pharma Said to Take Orders This Week for Hong Kong IPO

Guangzhou Innogen Pharmaceutical Group Co. plans to take investor orders as soon as this week for its initial public offering in Hong Kong, people familiar with the matter said. The diabetes and ...
Barron's

Guangzhou Innogen Pharmaceutical Group Co. Ltd.

About Guangzhou Innogen Pharmaceutical Group Co. Ltd. Guangzhou Innogen Pharmaceutical Group Co., Ltd. engages in the production and distribution of pharmaceutical products. It offers heat clearing, ...